Loading...
XNAS
JAGX
Market cap4mUSD
Jun 16, Last price  
3.45USD
1D
-1.15%
1Q
1,308.16%
Jan 2017
-100.00%
IPO
-100.00%
Name

Jaguar Health Inc

Chart & Performance

D1W1MN
XNAS:JAGX chart
P/E
—
P/S
0.37
EPS
—
Div Yield, %
—
Shrs. gr., 5y
568.46%
Rev. gr., 5y
15.14%
Revenues
12m
+19.75%
0258,381141,5234,361,1864,416,1455,775,2579,385,0004,335,00011,956,0009,761,00011,689,000
Net income
-38m
L-6.80%
-8,609,575-16,291,550-14,733,780-21,968,614-32,146,057-38,539,436-36,791,000-60,251,000-47,454,000-41,300,000-38,492,000
CFO
-29m
L-11.61%
-5,463,218-14,315,863-14,413,718-9,824,940-22,730,832-20,456,806-15,278,000-34,970,000-33,104,000-33,241,999-29,384,000
Earnings
Aug 11, 2025

Profile

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
URL
https://jaguar.health/
IPO date
May 13, 2015
Employees
60
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
11,689
19.75%
9,761
-18.36%
11,956
175.80%
Cost of revenue
42,520
43,681
46,371
Unusual Expense (Income)
NOPBT
(30,831)
(33,920)
(34,415)
NOPBT Margin
Operating Taxes
(759)
(941)
Tax Rate
NOPAT
(30,072)
(33,920)
(33,474)
Net income
(38,492)
-6.80%
(41,300)
-12.97%
(47,454)
-21.24%
Dividends
Dividend yield
Proceeds from repurchase of equity
31,910
32,711
20,462
BB yield
-10.73%
-936.59%
-3.99%
Debt
Debt current
12,337
5,215
16,366
Long-term debt
25,174
33,113
19,677
Deferred revenue
Other long-term liabilities
553
Net debt
29,509
31,859
30,574
Cash flow
Cash from operating activities
(29,384)
(33,242)
(33,104)
CAPEX
(1,675)
Cash from investing activities
(231)
(1,675)
Cash from financing activities
31,202
34,227
23,181
FCF
(34,021)
(43,738)
(36,316)
Balance
Cash
8,002
6,469
5,469
Long term investments
Excess cash
7,418
5,981
4,871
Stockholders' equity
(347,740)
(308,957)
(268,327)
Invested Capital
393,798
350,948
301,221
ROIC
ROCE
EV
Common stock shares outstanding
294,534
384
1,312
Price
1.01
-88.88%
9.08
-97.68%
391.05
-91.64%
Market cap
297,479
8,417.53%
3,493
-99.32%
512,882
-81.62%
EV
326,197
35,288
542,757
EBITDA
(28,473)
(20,339)
(32,123)
EV/EBITDA
Interest
231
6,382
12,723
Interest/NOPBT